Company News: AstraZeneca, Bayer, Sanofi and Bristol-Myers Squibb

Share this article:

AstraZeneca has released Q2 financial information, reporting overall sales revenue increasing by 3% despite a decline of nearly $500 million due to generic competition. The company reports “strong double-digit growth” for products Symbicort (asthma medication), Crestor (for the treatment of high cholesterol), and Seroquel XR (for depressive disorders), which largely accounted for increased profits this quarter. AstraZeneca's Brilinta, an anti-platelet for heart attack prevention, was recently approved by the FDA for use in the US, in addition to the 40 other countries worldwide that have gained approval for the drug.

Bayer has reported sales in the second quarter as growing 0.8%, with a currency- and portfolio-adjusted growth of 5.4%. The company also reported that business in the emerging markets made an “above-average contribution” to these figures.

Sanofi reports Q2 sales as increasing by 6.9% due to the acquisition of biotech Genzyme, noting that with the exclusion of this acquisition, sales were down 4% due to generic competition. Diabetes sales, specifically, were up 12.4% due to products Lantus, Apidra and Lantus SoloSTAR.

Bristol-Myers Squibb has reported a 14% net sales increase for Q2, which the company maintains is in part due to the strong initial performance in the US of melanoma product Yervoy, kidney transplant medication Nulojix, and for VTE prevention product Eliquis in the EU. The company also reports a decrease in this quarter's ad and promotional spend by 4%, and an increase in R&D spend by 12%.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.